Long-term Effects of Small Doses of 1,25-dihydroxycholecalciferol in Renal Osteodystrophy
Overview
Affiliations
An oral dose of 0.5 microgram of 1,25-dihydroxycholecalciferol (1,25-[OH]2D3) and 4 g of calcium carbonate was given daily to two dialysed patients and three undialysed patients in chronic renal failure with renal osteodystrophy. Treatment was given for 4-16 months. Intestinal calcium absorption became normal in all five patients. Plasma alkaline phosphatase, hydroxyproline, and immunoreactive parathyroid hormone were considerably reduced in all of the patients and in four of them these values were restored to normal. Bone histology was improved in all patients after treatment with 1,25-(OH)2D3. As well as a dramatic improvement in bone mineralisation, there was remodeling of trabecular architecture and a decrease in fibrosis in patients with initial parathyroid overactivity.
Impaired arterial vitamin D signaling occurs in the development of vascular calcification.
Lim K, Molostvov G, Lubczanska M, Fletcher S, Bland R, Hiemstra T PLoS One. 2020; 15(11):e0241976.
PMID: 33211721 PMC: 7676703. DOI: 10.1371/journal.pone.0241976.
Zehnder D, Quinkler M, Eardley K, Bland R, Lepenies J, Hughes S Kidney Int. 2008; 74(10):1343-53.
PMID: 18784644 PMC: 2737358. DOI: 10.1038/ki.2008.453.
Boran M, Doruk E, Gonenc F, Cetin S Int Urol Nephrol. 1997; 29(2):251-8.
PMID: 9241557 DOI: 10.1007/BF02551351.
Treatment of renal osteodystrophy with 1,25-dihydroxycholecalciferol.
Velentzas C, Oreopoulos D, Pierratos A, MEEMA H, RABINOVICH S, MEINDOK H Can Med Assoc J. 1981; 124(5):577-83.
PMID: 6894103 PMC: 1705195.
Weisbrode S Am J Pathol. 1981; 104(1):35-40.
PMID: 6266257 PMC: 1903744.